Enzymatica AB (publ)
STO:ENZY
Net Margin
Enzymatica AB (publ)
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| SE |
E
|
Enzymatica AB (publ)
STO:ENZY
|
720.9m SEK |
-108%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
682B USD |
23%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
367.5B USD |
24%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2.1T DKK |
35%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
208.7B CHF |
14%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
184.1B CHF |
24%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
163.2B GBP |
14%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
194.8B USD |
27%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD |
-126%
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
116.6B EUR |
14%
|
Enzymatica AB (publ)
Glance View
Enzymatica AB engages in the research, development, and sale of medical technology products. The company is headquartered in Lund, Skane and currently employs 26 full-time employees. The company went IPO on 2011-06-14. The company researches, develops and registers enzyme-based health and wellbeing products. The firm uses a patented enzyme, Penzyme, a cold-adapted trypsin from deep sea cod. The enzyme is active at about 37 Celsius degree and decomposes disease-related proteins, counteracting viral and bacterial infections and supporting healing processes. The firm conducts clinical studies of ColdZyme Munspray, a cold medicine. The company operates such subsidiaries, as Enzymatica Care AB, Zymetech ehf, among others. Main shareholders of Enzymatica AB are Humea AB, Medi AB, and Nordic Consulting Group AB, among others. In November 2013, the Company established another subsidiary in the United States, Enzymatica North America Inc., responsible for future production and sale of veterinary products in the United States and Canada.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Enzymatica AB (publ)'s most recent financial statements, the company has Net Margin of -108%.
You don't have any saved screeners yet